AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

IMV Inc. to Present at Upcoming Investor Conferences

May 14, 2019

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--May 14, 2019--

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company today announced that IMV Chief Executive Officer Frederic Ors will present at the following investor conferences in May:

RBC Capital Markets Global Healthcare Conference

  • Date: Tuesday, May 21, 2019
  • Time: 1:35 p.m. ET
  • Location: The InterContinental New York Barclay Hotel, New York, NY

National Bank Financials’ 9 th Annual Quebec Conference

  • Date: Wednesday, May 29, 2019
  • Time: 9:50 a.m. ET
  • Location: Museum Room, Shangri-la Hotel, Toronto, Ontario

China Bio-Partnering Forum

  • Date: Thursday, May 30, 2019
  • Time: 1:40 p.m. CT
  • Location: Renaissance Schaumburg Convention Center Hotel, Chicago, IL

A copy of each meeting’s presentation will be available in the events and presentations section of IMV’s website. A live webcast of IMV’s presentation at the RBC Capital Markets conference will also be available and archived for 90 days on the events and presentations webpage.

About IMV

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells  in vivo,  which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a monotherapy in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. Connect at  www.imv-inc.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190514005899/en/

CONTACT: Investor Relations:

Marc Jasmin, IMV Senior Director, Investor Relations and Communications

O: (902) 492-1819 ext : 1042

M: (514) 617-9481 E:mjasmin@imv-inc.comMedia:

Andrea Cohen, Sam Brown Inc.

T: (917) 209-7163 E: andreacohen@sambrown.com

KEYWORD: UNITED STATES NORTH AMERICA CANADA ILLINOIS NEW YORK

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PUBLIC POLICY/GOVERNMENT HEALTHCARE REFORM PHARMACEUTICAL RESEARCH OTHER SCIENCE SCIENCE

SOURCE: IMV Inc.

Copyright Business Wire 2019.

PUB: 05/14/2019 05:05 PM/DISC: 05/14/2019 05:05 PM

http://www.businesswire.com/news/home/20190514005899/en